Skip to main navigation
Skip to search
Skip to main content
Utrecht University Home
Help & FAQ
Home
Research output
Search by expertise, name or affiliation
What Happens To Originator Medicines When (Generic) Followers Enter The Public Market
C. Habl,
Christine Leopold
Austria Public Health Institute GÖG, Vienna
Harvard Medical School & Harvard Pilgrim Institute, Boston, MA
Research output
:
Contribution to journal
›
Meeting Abstract
›
Academic
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'What Happens To Originator Medicines When (Generic) Followers Enter The Public Market'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Estonia
100%
Public Markets
100%
Delisting
60%
Poland
40%
Atorvastatin
40%
Originator Brand
40%
Clopidogrel
40%
Olanzapine
40%
National Formulary
40%
Pharmaceutical Companies
20%
European Countries
20%
Valproic Acid
20%
Czech Republic
20%
Hungary
20%
External Reference Pricing
20%
Bulgaria
20%
Iceland
20%
Paroxetine
20%
Publicly Funded
20%
Latvia
20%
Omeprazole
20%
Feature Information
20%
Market Entry
20%
Slovakia
20%
Pfizer
20%
Dissemination Strategy
20%
Pricing Regulations
20%
Off-patent
20%
Generic Market
20%
Generic Entry
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clopidogrel
100%
Olanzapine
100%
Atorvastatin
100%
Sodium Valproate
50%
Omeprazole
50%
Paroxetine
50%